Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti Sells 16,500 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded up $0.95 during mid-day trading on Monday, reaching $29.34. 1,268,326 shares of the company’s stock traded hands, compared to its average volume of 1,493,931. The stock has a market cap of $2.99 billion, a P/E ratio of -8.24 and a beta of 1.10. Dyne Therapeutics, Inc. has a 1-year low of $10.03 and a 1-year high of $47.45. The business has a 50-day simple moving average of $32.42 and a 200 day simple moving average of $35.26.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on DYN shares. Stifel Nicolaus lifted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Chardan Capital reissued a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, Guggenheim increased their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently added to or reduced their stakes in DYN. Swiss National Bank grew its holdings in Dyne Therapeutics by 41.5% during the 1st quarter. Swiss National Bank now owns 85,200 shares of the company’s stock valued at $2,419,000 after buying an additional 25,000 shares in the last quarter. Sei Investments Co. bought a new stake in Dyne Therapeutics during the 1st quarter worth approximately $693,000. Russell Investments Group Ltd. lifted its stake in Dyne Therapeutics by 1.4% in the 1st quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company’s stock worth $2,894,000 after purchasing an additional 1,447 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Dyne Therapeutics by 44.6% in the 1st quarter. ProShare Advisors LLC now owns 16,307 shares of the company’s stock valued at $463,000 after purchasing an additional 5,028 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.